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Objective: Bone morphogenic protein 2 is found in calcified areas of stenotic aortic valves, and prolonged stim-
ulation of aortic valve interstitial cells with bone morphogenic protein 2 results in increased expression of alkaline
phosphatase, indicating a mechanistic role for bone morphogenic protein 2 in aortic valve calcification. The pur-
poses of this study were to assess the effect of bone morphogenic protein 2 on the expression of the osteogenic
factors Runx2 and osteopontin in human aortic valve interstitial cells and to determine the signaling mechanisms
that mediate the expression of these early osteogenic factors.
Methods: Interstitial cells were isolated from normal and stenotic human aortic valve leaflets, and cellular bone
morphogenic protein 2 levels were analyzed by means of immunoblotting. Cultured interstitial cells from normal
aortic valves were stimulated with bone morphogenic protein 2 to determine its effect on cellular Runx2 and
osteopontin levels.
Results: Interstitial cells from stenotic aortic valves express greater levels of bone morphogenic protein 2 than
cells from normal valves. Stimulation of human aortic valve interstitial cells with bone morphogenic protein 2
induced marked increases in Runx2 and osteopontin levels at 48 hours. The changes in Runx2 and osteopontin
levels were preceded by phosphorylation of Smad1 and extracellular signal-regulated kinase 1/2 but not p38
mitogen-activated protein kinase. Silencing Smad1 reduced Runx2 and osteopontin levels, whereas inhibition
of extracellular signal-regulated kinase 1/2 reduced osteopontin expression without an influence on Runx2
expression.
Conclusions: Interstitial cells of stenotic human aortic valves are characterized by increased bone morphogenic
protein 2 levels. A short period of exposure of human aortic valve interstitial cells to bone morphogenic protein 2
induces the expression of Runx2 and osteopontin. The extracellular signal-regulated kinase 1/2 pathway modu-
lates bone morphogenic protein 2–induced osteopontin expression, and the Smad1 pathway plays a role in reg-
ulating the expression of both Runx2 and osteopontin induced by bone morphogenic protein 2.Supplemental material is available online.
Calcific aortic stenosis is the third leading cardiovascular
disease behind only hypertension and coronary artery dis-
ease.1 It is found in approximately 3% of the population
older than 65 years and is the most common indication for
heart valve replacement surgery.2 Long considered a disease
of passive degeneration, evidence has emerged that aortic
stenosis might result from an active disease process. How-
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aortic stenosis remain unclear.
Insight into the pathogenesis of calcific aortic stenosis has
been gained from the examination of aortic valve leaflets
explanted at aortic valve replacement. Explanted calcified
valve leaflets demonstrate morphologic features resembling
osteogenic bone formation, as well as the expression of pro-
teins associated with bone formation.3 The fact that diseased
aortic valve leaflets have such a histologic appearance sug-
gests that calcific aortic stenosis might result from a process
similar to that of active bone formation. This further implies
that bone-forming cells (osteoblast-like cells) might be re-
sponsible for the calcification. Although the origin of such
bone-forming cells is unclear, aortic valve interstitial cells
(ICs) have been shown to have the ability to become osteo-
blast-like cells.4
Bone morphogenic proteins are osteogenic growth factors
that belong to the transforming growth factor b superfamily.
These osteogenic growth factors are the principal inducers
of osteoblast differentiation and bone formation. They act
through both autocrine and paracrine mechanisms, and thergery c October 2009
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BMP-2 ¼ bone morphogenic protein 2
ERK ¼ extracellular signal-regulated kinase
IC ¼ interstitial cell
MAPK ¼ mitogen-activated protein kinase
PBS ¼ phosphate-buffered saline
siRNA ¼ small interfering RNA
paracrine effects are particularly important in osteogenesis.5
Bone morphogenic protein 2 (BMP-2) has been found to
play critical roles in vascular calcification.6 This osteogenic
growth factor has been identified in calcified tissue of ste-
notic aortic valves.7,8 Likewise, the bone-forming protein
osteopontin has been found in calcified aortic valve leaflets.2
However, whether aortic valve ICs can be stimulated to pro-
duce osteopontin is unclear. After stimulation with BMP-2,
the production of bone-forming proteins, such as osteopon-
tin, requires the production of the transcription factor Runx2
in certain cell types. Hence in the present study the produc-
tion of osteopontin and Runx2 after stimulation with BMP-2
was studied.
Although ICs appear to play an important role in aortic
valve calcification,9 it is unclear whether BMP-2 expres-
sion in ICs is altered in stenotic aortic valves. In a recent
study10 we isolated ICs from the noncalcified tissue of ste-
notic aortic valves and found that they are phenotypically
different from ICs of normal valves. Analysis of BMP-2
expression in ICs of stenotic aortic valves might provide
insights into the pathophysiology of aortic valve stenosis
and calcification.
Previous studies by our group and others have found that
stimulation of human aortic valve ICs for 2 or 3 weeks with
BMP-2 upregulates the expression of alkaline phospha-
tase.4,10 In C2C12 cells, BMP-2 activates the Runx2 path-
way through Smad and p38 mitogen-activated protein
kinase (MAPK).11-13 The roles of the Smad and p38
MAPK pathways in mediating the effect of BMP-2 on hu-
man aortic valve ICs remain unclear. Further determination
of the effect of BMP-2 on human aortic valve IC osteogenic
response and the underlying signaling mechanisms is impor-
tant to elucidate the role of BMP-2 in the pathogenesis of
aortic valve calcification and stenosis.
In the present study we sought to determine (1) whether
ICs of stenotic human aortic valves express higher levels
of BMP-2, (2) the effect of BMP-2 on the expression of
the early osteogenic factors Runx2 and osteopontin in hu-
man aortic valve ICs, and (3) the signaling mechanisms
that mediate the effect of BMP-2 on the expression of these
early osteogenic factors.
The results of the present study offer mechanistic insight
into the pathogenesis of calcific aortic stenosis. The ICs ofThe Journal of Thoracic and Castenotic human aortic valves were found to be characterized
by increased BMP-2 levels. Exposure of normal human aor-
tic valve ICs to BMP-2 induces the expression of Runx2 and
osteopontin. The extracellular signal-regulated kinase
(ERK) 1/2 pathway modulates BMP-2–induced osteopontin
expression, and the Smad1 pathway plays a role in regulat-
ing the expression of both Runx2 and osteopontin induced
by BMP-2.
MATERIALS AND METHODS
Chemicals and Reagents
M199 medium and human serum albumin were purchased from Lonza
(Walkersville, Md). Rabbit polyclonal antibody against human BMP-2
was obtained from ProSci (Poway, Calif). Rabbit polyclonal antibody
against Runx2 was purchased from Novus Biologicals (Littleton, Colo).
Rabbit polyclonal antibody against osteopontin was purchased from Abcam
(Cambridge, Mass). Antibodies against phosphorylated and nonphosphory-
lated Smad1, ERK1/2, and p38MAPK were purchased from Cell Signaling
Technology (Danvers, Mass). Recombinant human BMP-2 was obtained
from R&D Systems (Minneapolis, Minn). PD98059 was purchased from
Calbiochem (San Diego, Calif). Smad1 small interfering RNA (siRNA)
and DharmaFECT1 transfection reagent were purchased from Dharmacon
(Lafayette, Colo). Opti-MEM _ medium was purchased from Invitrogen
(Carlsbad, Calif). Collagenase and other reagents were purchased from
Sigma (St Louis, Mo).
Cell Isolation and Culture
Normal aortic valves were collected from 5 explanted hearts of heart
transplant recipients with cardiomyopathy (3 male and 2 female patients
49–65 years old), and stenotic aortic valves were collected from 5 patients
who underwent valve replacement surgery for calcific aortic stenosis
(2 male and 3 female patients 53–72 years old). All valves were tricuspid.
This study was approved by the Colorado Multiple Institutional Review
Board, and all patients provided written informed consent. On gross exam-
ination, normal valve leaflets were thin, and their surfaces were smooth.
Microscopic examination of hematoxylin and eosin–stained cryosections
confirmed that no leukocytes had infiltrated the leaflets. All stenotic valves
were thick and exhibited overt calcification. Noncalcific tissue was used for
cell isolation.
Small portions of each valve were either processed into tissue ho-
mogenate, frozen in OCT for tissue staining, or used for IC isolation.
ICs were isolated by means of collagenase digestion, as previously de-
scribed,10,14 and cultured in growth medium (M199 medium with pen-
icillin G, streptomycin, amphotericin B, and 10% fetal bovine serum)
in an incubator supplied with 5% CO2. Cells of passage 1 were used
for analysis of cellular BMP-2 levels. Cells of passages 3 to 5 were
grown to approximately 90% confluence and treated with recombinant
human BMP-2 (100 ng/mL) for a varied period of time to examine
the osteogenic response.
Immunohistochemistry
Immunohistochemical detection of BMP-2 protein in aortic valve leaf-
lets was performed by using the biotin-linked peroxidase technique. Cry-
osections (5 mm) were prepared and dried at room temperature for 2
hours. Sections were fixed with 4% paraformaldehyde in phosphate-buff-
ered saline (PBS) at room temperature for 10 minutes and then washed
with PBS. Unless indicated, all incubations were performed at room tem-
perature. Endogenous peroxidase activities were quenched by incubating
sections with 1% H2O2 in methanol for 10 minutes. Sections were incu-
bated for 30 minutes with 10% goat serum in PBS to block nonspecific
binding sites. Sections were then incubated for 90 minutes with rabbitrdiovascular Surgery c Volume 138, Number 4 1009
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SFIGURE 1. Stenotic aortic valves express higher levels of bone morphogenic protein 2 (BMP-2). A representative immunoblot of aortic valve tissue homog-
enates (A) and immunohistochemical staining of aortic valve leaflets (B) show that stenotic human aortic valves produced higher levels of BMP-2 than normal
valves. BMP-2 is represented by the brown color in the immunohistochemistry images. The black bar in the lower left corner of each image represents 20 mm.
Aortic valve interstitial cells isolated from stenotic valves also have higher levels of BMP-2 than cells isolated from normal valves (C).HAVIC, Human aortic
valve interstitial cells.polyclonal antibody against BMP-2 (5 mg/mL in PBS containing 10%
goat serum) followed by a 60-minute incubation with biotinylated goat
anti-rabbit IgG (1:200 dilution with PBS containing 10% goat serum)
from the Rabbit ABC Staining System (Santa Cruz Biotechnology). Sub-
sequently, sections were washed 3 times with PBS and incubated with
avidin–biotin–peroxidase complex (1:50 dilution with PBS) for 30 minutes.
After thorough washes with PBS, color development was carried out
with peroxidase substrate (0.03% H2O2 and 0.05% diaminobenzidine in
double-distilled H2O). Sections were counterstained with hematoxylin and
eosin.
Silencing Smad1
A transfection mixture of Smad1 siRNA (60 or 90 nmol/L) and Dharma-
FECT1 transfection reagent (0.5 mL/mL) was made in Opti-MEM _ reduced
serum medium. ICs were incubated with the transfection mixture in com-
plete medium for 48 hours, which we found to be the optimal transfection
time. Cells were incubated in growth medium for 24 hours after transfection
and then stimulated with BMP-2. Controls were treated with scrambled
siRNA (90 nmol/L) and DharmaFECT1 transfection reagent. Table E1 lists
the sequences of sense and antisense siRNA nucleotides.
Immunoblotting
Cell lysates were separated on 4% to 20%minigels and transferred onto
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, Calif). After
blocking with 5% fat-free milk solution, the protein of interest was detected
by using a primary antibody and a corresponding peroxidase-linked second-
ary antibody (Cell Signaling Technology) diluted 1:5000. Blots were devel-1010 The Journal of Thoracic and Cardiovascular Soped with ECL reagent and exposed on x-ray film. Films were scanned, and
Image J software was used to quantitate band density.
Statistical Analysis
Densitometric data from more than 2 groups were compared and ana-
lyzed by means of analysis of variance with the post hoc Fisher’s test,
and single comparisons were made with the unpaired t test. Statistical sig-
nificance was accepted within a 95% confidence limit.
RESULTS
Stenotic Aortic Valves and ICs From Stenotic Valves
Express Higher Levels of BMP-2
We have previously reported the BMP-2 protein levels
are higher in cells of stenotic aortic valves than in nor-
mal valves after stimulation of Toll-like receptors.10 In
the present study we used immunoblotting to examine
BMP-2 protein levels in ICs isolated from normal and
stenotic aortic valves. We confirmed that BMP-2 protein
levels were markedly higher in tissue from stenotic
valves (Figure 1, A and B), as well as in cells isolated
from stenotic aortic valves (Figure 1, C). BMP-2 local-
izes to the valvular ICs on immunohistochemical stain-
ing and appears to have a cytoplasmic distribution
(Figure 1, B). Therefore ICs constitute an importanturgery c October 2009
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tic valve.
BMP-2 Upregulates Runx2 and Osteopontin Protein
Levels in Human Aortic Valve ICs
Previous studies by our group and others have shown
that prolonged stimulation of human aortic valve ICs
with BMP-2 upregulates the protein level of alkaline
FIGURE 2. Bonemorphogenic protein 2 (BMP-2) induces Runx2 and osteo-
pontin expression in interstitial cells. A, Representative immunoblot shows that
BMP-2 stimulation induced Runx2 expression at 24 hours, and cellular Runx2
level increased further with 48 hours of stimulation. B, Osteopontin levels in-
creased in interstitial cells stimulated with BMP-2 for 48 hours in comparison
with those seen in control (Ctrl; untreated) cells. C, Densitometric data show
that bothRunx2 andosteopontin levels are significantly increased after 48 hours
of BMP-2 stimulation. Data are expressed as means standard errors (n¼ 3).
*P< .05 versus control.The Journal of Thoracic and Caphosphatase, a marker of osteogenic phenotypic
change.4,10 To further study the effect of BMP-2 on the
osteogenic response in human aortic valve ICs, we stim-
ulated cells from normal aortic valves with BMP-2 for 24
to 48 hours and determined its effect on cellular Runx2
and osteopontin levels. Stimulation with BMP-2 in-
creased Runx2 (Figure 2, A) and osteopontin (Figure 2,
B) levels. At 48 hours, cellular Runx2 levels increased
29-fold and osteopontin levels increased 2.3-fold
(Figure 2, C). Thus the results demonstrate that BMP-2
upregulates the expression of early osteogenic factors in
human aortic valve ICs.
BMP-2 Activates the Smad1 and ERK1/2 Pathways,
but Not the p38 MAPK Pathway, in Human Aortic
Valve ICs
To examine the signaling pathways involved in the BMP-
2–induced osteogenic response, we treated the cells for 10
minutes to 2 hours and analyzed phosphorylation of
Smad1, ERK1/2, and p38 MAPK. Phosphorylated Smad1
was detected at 30 minutes and reached a peak after 60 min-
utes (Figure 3). ERK1/2 phosphorylation reached a maxi-
mum at 30 minutes (Figure 3). However, p38 MAPK
phosphorylation was not detected during the 2-hour stimula-
tion with BMP-2 (Figure 3). Thus BMP-2 activates the
Smad1 and ERK1/2 pathways, but not the p38 MAPK path-
way, in human aortic valve ICs.
FIGURE 3. Bone morphogenic protein 2 (BMP-2) induces Smad1 and
extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in
interstitial cells. Representative immunoblots of 2 separate experiments
show that BMP-2 induced rapid phosphorylation of Smad1 and ERK1/
2. Peak Smad1 phosphorylation was at 60 minutes, and peak ERK1/2
phosphorylation was at 30 minutes. However, BMP-2 stimulation failed
to induce p38 mitogen-activated protein kinase phosphorylation in inter-
stitial cells.rdiovascular Surgery c Volume 138, Number 4 1011
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SFIGURE 4. Silencing Smad1 reduces the expression of both Runx2 and osteopontin after bone morphogenic protein 2 (BMP-2) stimulation, whereas in-
hibiting extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation only reduces expression of osteopontin. A, Treatment with Smad1 small inter-
fering RNA (siRNA) at concentrations of 60 and 90 nmol/L reduced cellular Smad1 levels by 25% and 51%, respectively. B, Pretreatment of cells with Smad1
siRNA at 90 nmol/L reduced Runx2 and osteopontin levels after 48 hours of BMP-2 stimulation. C, Densitometric data show that silencing Smad1 reduced
BMP-2–induced expression of Runx2 and osteopontin by 54% and 46%, respectively. Data are expressed as means standard errors (n¼ 3). *P<.05 versus
untreated control and scrambled RNA control. D, Treatment with PD 98059 (PD; 25 mmol/L) markedly reduced ERK1/2 phosphorylation induced by BMP-2,
whereas vehicle dimethyl sulfoxide (DMSO) had no effect. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase. E, Inhibition of ERK1/2 had no effect on
BMP-2–induced Runx2 expression. In contrast, it reduced cellular osteopontin level after BMP-2 stimulation. F, Densitometric data show that inhibition of
ERK1/2 reduced BMP-2–induced osteopontin expression by 76%. Data are expressed as means standard errors (n¼ 3). *P<.05 versus untreated control
and DMSO control.Smad1 and ERK1/2 Pathways Differentially
Regulate BMP-2–Induced Runx2 and Osteopontin
Expression
Because BMP-2 stimulation activates the Smad1 and
ERK1/2 pathways in human aortic valve ICs, we deter-
mined their roles in modulating the expression of Runx2
and osteopontin induced by BMP-2. We used siRNA to
silence Smad1. As shown in Figure 4, A, treatment of cells
with Smad1 siRNA reduced Smad1 protein levels by 25%
(60 nmol/L siRNA) and 51% (90 nmol/L siRNA). Using
Smad1 siRNA at a concentration of 90 nmol/L, we found
that silencing Smad1 reduced the expression of both
Runx2 and osteopontin after BMP-2 stimulation by 54%1012 The Journal of Thoracic and Cardiovascular Suand 46%, respectively (Figure 4, B and C). We used the
specific ERK1/2 inhibitor PD 98059 to determine whether
the ERK1/2 pathway is involved in the BMP-2–induced
expression of Runx2 and osteopontin. Figure 4, D, shows
that PD 98059 at 25 mmol/L markedly reduced BMP-
2–induced ERK1/2 phosphorylation. Interestingly, PD
98059 reduced osteopontin expression by 76% but had
no effect on Runx2 expression induced by BMP-2
(Figure 4, E and F). These results demonstrate that the
Smad1 pathway plays a role in regulating the expression
of both Runx2 and osteopontin induced by BMP-2,
whereas the ERK1/2 pathway modulates BMP-2–induced
osteopontin expression.rgery c October 2009
Yang et al Evolving Technology/Basic ScienceFIGURE 5. Schematic illustration of the role of bone morphogenic protein 2 (BMP-2) in the development of an osteogenic phenotype in human aortic valve
interstitial cells. PD, PD 98059; Erk1/2, extracellular signal-regulated kinase 1/2; siRNA, small interfering RNA.E
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The results of the present study demonstrate that ICs of
stenotic aortic valves express higher levels of BMP-2. Fur-
thermore, the results demonstrate that BMP-2 induces the
osteogenic biomarkers Runx2 and osteopontin in human
aortic valve ICs in vitro. The Smad1 pathway is required
for both Runx2 and osteopontin expression, whereas the
ERK1/2 pathway mediates osteopontin expression. These
data suggest that the actions of BMP-2 in ICs might
play a mechanistic role in the pathogenesis of calcific aortic
stenosis.
Several studies have found BMP-2 accumulation in cal-
cification foci of stenotic aortic valves.7,8 The results of
the present study expand on these observations and dem-
onstrate that ICs isolated from stenotic valves express
significantly higher levels of BMP-2, demonstrating that
ICs constitute an important source of BMP-2 in diseased
aortic valves. It is possible that BMP-2 from aortic valve
ICs exerts a paracrine effect on neighboring ICs and other
cells to promote calcification. The mechanism underlying
the upregulated BMP-2 expression remains unknown from
this study; however, proinflammatory cytokines, such as
tumor necrosis factor a and interleukin 1b, have been
found to induce BMP-2 expression in human aortic valve
ICs in vitro.15,16 Work from our laboratory has previously
demonstrated that stimulation of Toll-like receptors 2 and
4, 2 important innate immune receptors involved in the
mediation of mechanisms of inflammation, also upregu-The Journal of Thoracic and Calates BMP-2 expression in human aortic valve ICs at
both the mRNA and protein levels.14,17 It is likely that
proinflammatory mechanisms are involved in the upregu-
lation of BMP-2 expression in ICs of stenotic aortic
valves.
Previous studies have demonstrated that prolonged
stimulation of human aortic valve ICs with BMP-2 induces
an osteogenic phenotypic change characterized by overex-
pression of alkaline phosphatase, indicating a critical role
for this osteogenic growth factor in valvular cell calcifica-
tion.4,10 Indeed, work from our laboratory has demon-
strated that the bone morphogenic protein antagonist
noggin reduces alkaline phosphatase expression and cal-
cific nodule formation in human aortic valve ICs exposed
to proinflammatory stimuli.10 These findings highlight the
potential role of BMP-2 in aortic valve stenosis and calci-
fication. In the present study, we determined the effect of
BMP-2 on the expression of the early osteogenic mediators
Runx2 and osteopontin in human aortic valve ICs. The
results of the present study demonstrate that stimulation
of cells in vitro with BMP-2 for 48 hours increased cellular
Runx2 and osteopontin levels by 29- and 2.3-fold, respec-
tively. The potent effect of BMP-2 on Runx2 expression is
particularly interesting because Runx2 is an important tran-
scription factor in regulating fibroblast differentiation and
bone formation.18 Higher Runx2 levels might promote
osteoblast-like phenotypic changes in human aortic valve
ICs. Further study is necessary to determine the role ofrdiovascular Surgery c Volume 138, Number 4 1013
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alkaline phosphatase and calcification.
The intracellular BMP-2 signaling pathway has been ex-
tensively studied in osteoblasts and chondroblasts.19 BMP-
2 has been shown to activate Runx2 through Smad1 and
p38 MAPK in C2C12 and other mesenchymal cells.11-13
The results of the present study demonstrate that in human
aortic valve ICs BMP-2 induces rapid phosphorylation of
Smad1 and ERK1/2 but has no effect on p38 MAPK phos-
phorylation, indicating that it activates the Smad1 and
ERK1/2 pathways to upregulate the expression of Runx2
and osteopontin. We used siRNA and a specific inhibitor to
determine the roles of Smad1 and ERK1/2 in the osteogenic
response to BMP-2. Silencing Smad1 reduced BMP-2–in-
duced expression of Runx2 and osteopontin, indicating that
the Smad1 pathway is required for the induction of the oste-
ogenic response by BMP-2 in human aortic valve ICs. How-
ever, inhibition of ERK1/2 only reduced osteopontin
expression. It is noteworthy that inhibition of ERK1/2 re-
duced cellular osteopontin levels by 76%, indicating the
ERK1/2 pathway has a major role in regulating BMP-2–in-
duced osteopontin expression. It appears that the Smad1
pathway selectively regulates Runx2 expression, whereas
the Smad1 and ERK1/2 signaling pathways have an overlap-
ping function in the regulation of osteopontin expression.
Signaling pathways might communicate or cross-talk in reg-
ulation of cellular response to stimuli. The Smad1 pathway
might interact with the ERK1/2 pathway.20 Further study is
needed to determine whether Smad1 is involved in ERK1/2
activation in the signaling mechanisms underlying the osteo-
genic response to BMP-2 in human aortic valve ICs.
Calcific aortic stenosis has long been considered a degen-
erative disease, one in which calcium passively accumulates
on the leaflets of the valve. However, some investigators
have suggested that the pathogenesis of calcific aortic steno-
sis might be an active disease process involving osteogene-
sis.2 Another contributing mechanism might also be that of
ectopic calcification of the aortic valve. Ectopic tissue calci-
fication is a process by which hydroxyapatite crystals are de-
posited in tissue; hydroxyapatite crystals can be found in the
leaflets of aortic stenosis. Although the results of the present
study are consistent with the possibility that mechanisms of
osteogenesis might contribute to the pathogenesis of aortic
stenosis, speculation as to the type of osteogenesis is not
possible.
The results of the present study are consistent with our
global hypothesis that aortic valve ICs might contribute to
the pathogenesis of calcific stenosis by changing their phe-
notype and behaving as bone forming–like cells. Future
work will focus on examination of the possible links
between mechanisms of inflammation and mechanisms
of osteogenesis in the pathogenesis of aortic stenosis. A
limitation of the present study, however, is the fact that
it only studied isolated aortic ICs from healthy valves. Be-1014 The Journal of Thoracic and Cardiovascular Sufore studying the mechanisms of stenosis with cells from
stenotic valves, we believed that it was first important to
gain an understanding of these mechanisms in normal
valve cells. Future studies with ICs from stenotic valves
will be undertaken once the intracellular signal transduc-
tion pathways of ICs from healthy valve cells are better
understood. Another limitation is that we studied isolated
ICs in culture. All such studies are limited by the possibil-
ity that the behavior of cells in vitro might differ from that
in vivo.
In conclusion, the present study found that ICs of ste-
notic human aortic valves are characterized by increased
BMP-2 levels. A short period of exposure of human aortic
valve ICs to BMP-2 induces the expression of Runx2 and
osteopontin. The ERK1/2 pathway modulates BMP-2–in-
duced osteopontin expression, and the Smad1 pathway
plays a role in regulating the expression of both Runx2
and osteopontin induced by BMP-2 (Figure 5). The results
of the present study offer mechanistic insight into the path-
ogenesis of calcific aortic valve stenosis.
We thank Yimu Yang, MD, PhD, for his technical assistance
with immunohistochemical staining.
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STABLE E1. Sequences of Smad1 siRNA and scrambled siRNA
Knockdown siRNA pool
Smad1 Sense 50-GCUCUAUUGUCUACUAUGAUU-30
Antisense 50-PUCAUAGUAGACAAUAGAGCUU-30
Sense 50-GGCGGUUGCUUAUGAGGAAUU-30
Antisense 50-PUUCCUCAUAAGCAACCGCCUU-30
Sense 50-CAACAAUCGUGUGGGUGAAUU-30
Antisense 50-PUUCACCCACACGAUUGUUGUU-30
Sense 50-CAAAUGGGUUCACCUCAUAUU-30
Antisense 50-PUAUGAGGUGAACCCAUUUGUU-30
Scrambled
siRNA
Sense 50-UAGCGACUAAACACAUCAAUU-30
Antisense 50-PUUGAUGUGUUUAGUCGCUAUU-30
siRNA, Small interfering RNA.1015.e1 The Journal of Thoracic and Cardiovascular Surgery c October 2009
